Geographic Access to Global Innovation

Which pharmaceutical companies can source innovation from all three power centers?

AstraZeneca
United Kingdom • LSE: AZN
Unrestricted
US Biotech
✓ Full Access
Chinese Innovation
✓ Full Access
European R&D
✓ Full Access
Roche
Switzerland • SIX: ROG
Unrestricted
US Biotech
✓ Full Access
Chinese Innovation
✓ Full Access
European R&D
✓ Full Access
Novartis
Switzerland • NYSE: NVS
Unrestricted
US Biotech
✓ Full Access
Chinese Innovation
✓ Full Access
European R&D
✓ Full Access
Eli Lilly
United States • NYSE: LLY
Potentially Constrained
US Biotech
✓ Full Access
Chinese Innovation
⚠ BIOSECURE Uncertain
European R&D
✓ Acquisitions Only
Pfizer
United States • NYSE: PFE
Potentially Constrained
US Biotech
✓ Full Access
Chinese Innovation
⚠ BIOSECURE Uncertain
European R&D
✓ Acquisitions Only
Understanding BIOSECURE Impact
Unrestricted: Can partner with Chinese CROs, license innovations, acquire biotechs globally without regulatory constraints
Potentially Constrained: Senate BIOSECURE targets BGI/MGI (DoD 1260H list). House reconciliation could expand to WuXi entities affecting 79% of US biopharma